Avitia's technology, developed in collaboration with Imagia Canexia Health and Mila, addresses the challenge of timely genomic testing, enabling on-site next-generation sequencing (NGS) tests that reduce turnaround times and costs. The platform's AI-driven bioinformatics cater to regional and patient-specific needs, empowering oncologists to make data-driven decisions. The technology has shown potential in improving patient monitoring and treatment response, particularly for aggressive cancers. Avitia's efforts are supported by Montréal International and Mila, highlighting the region's prominence in AI and life sciences.
Key takeaways:
- Avitia has launched an AI-powered platform for rapid and point-of-care cancer testing, supported by a $5M seed investment from PacBridge Capital Partners.
- The platform allows laboratories and clinicians to conduct advanced molecular testing on-site, reducing costs and accelerating treatment for cancer patients.
- Avitia's technology, used in Canada, the United States, and Southeast Asia, has already facilitated over 40,000 cancer mutation tests, improving global cancer care.
- The company collaborates with organizations like Mila to enhance AI-driven cancer diagnostics, aiming to provide precise and personalized care for patients worldwide.